Resumen
INTRODUCCIÓN:El diagnóstico oportuno del trastorno neurocognitivo es de los principales retos en la atención de los trastornos neurocognitivos. Por esto, se han generado estrategias para la detección preclínica de la enfermedad, entre ellas las destinadas a evaluar síntomas neuropsiquiátricos (NPS) como la escala Mild Behavior Impairment - Checklist (MBI-C).
MÉTODOS:Inicialmente se realizó una búsqueda en BVSalud, Medline y PsycNet, luego se realizó una búsqueda en bola de nieve. Se incluyeron términos referentes a deterioro comportamental leve (abarcando los NPS en etapas tempranas), deterioro cognitivo leve y términos específicos del MBI-C.
RESULTADOS:La presencia de NPS se asocia con un aumento en la incidencia anual de demencia. Al evaluarlos con MBI-C, su puntuación se correlaciona con biomarcadores como una mayor atrofia cortical, la presencia de la proteína ?-amiloide, así como disminución en funciones ejecutivas como la capacidad de enfocar la atención y la memoria de trabajo.
DISCUSIÓN:Los hallazgos en la literatura sugieren la utilidad de MBI-C como marcador de neurodegeneración en estadios previos a la demencia, esto mediante la evaluación de su capacidad predictiva de forma independiente y al compararla con otros biomarcadores.
CONCLUSIONES:MBI-C supone ser un instrumento de fácil aplicabilidad e interpretación, sostenible e incluyente. Sin embargo, quedan vacíos sobre la pertinencia de esta escala, por lo que surge la necesidad de investigar este tema.
Citas
Organización Mundial de la Salud. La salud mental y los adultos mayores [Internet]. 2017 [cited 2020 Jun 4]. Available from: Available from: https://www.who.int/es/news-room/fact-sheets/detail/la-salud-mental-y-los-adultos-mayores
Dávila-Cervantes CA, Pardo-Montaño AM. Cambios en la esperanza de vida por causas de muertes crónicas en adultos mayores. México 2000-2013. Rev Cienc Salud. 2017;15(2):223-35.
Ministerio de Salud y Protección Social. Envejecimiento demográfico. Colombia 1951-2020 Dinámica demográfica y estructuras poblacionales Promoción Social. Bogotá; 2013.
Alzheimer's Disease International, World Health Organization. Dementia. A public health priority. 2015.
Duong S, Patel T, Chang F. Dementia: What pharmacists need to know. Can Pharm J (Ott). 2017;150(2):118-29.
Organización Mundial de la Salud. Demencia [Internet]. OMS. 2020 [cited 2020 Aug 26]. Available from: Available from: https://www.who.int/es/news-room/fact-sheets/detail/dementia
International AD, Patterson C. World Alzheimer Report 2018: The state of the art of dementia research: New frontiers. 2018.
Pradilla A, Vesga A, Boris B, León-Sarmiento F, Rosselli D, Bautista L, et al. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Rev Panam Salud Publica. 2003;14(2):104-11.
Ministerio de Salud y Protección Social. Boletín de salud mental. Bogotá; 2017.
Boise L, Camicioli R, Morgan DL, Rose JH, Congleton L. Diagnosing dementia: Perspectives of primary care physicians. Gerontologist. 1999;39(4):457-64.
Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Inter Med. 1995;122(6):422-9.
Shao Y, Zeng QT, Chen KK, Shutes-David A, Thielke SM, Tsuang DW. Detection of probable dementia cases in undi-agnosed patients using structured and unstructured electronic health records. BMC Med Inform Decis Mak. 2019;19(1):128. doi: 10.1186/s12911-019-0846-4
Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: Prevalence and contributing factors. Alzheimer Dis Associated Disord. 2009;23(4):306-14.
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-46.
Roberts RO, Aakre JA, Kremers WK, Vassilaki M, Knopman DS, Mielke MM, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 2018;75(8):970-9.
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-3 biomarkers for Alzheimer's disease. Nature. 2018;554(7691):249-54.
Sandelius A, Cullen NC, Kãllén A, Rosengren L, Jensen C, Kostanjevecki V, et al. Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurol. 2018;18(1):202.
Khoury R, Ghossoub E. Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review. Biomarkers in Neuropsychiatry. 2019;1:100005.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in predementia populations. J Alzheimer Dis. 2017;56(3):929-38.
Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195-202.
International Psychogeriatric Association. The IPA complete guides to behavioral and psychological symptoms of dementia. 2015.
Elefante C, Lattanzi L, Ismail Z, Medda P, Bacciardi S, Mainardi C, et al. Mild Behavioral Impairment: presentation of the diagnostic criteria and the Italian version of the MBI-Checklist. Riv Psichiatr. 2019;54(2):59-66.
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, Dekosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA. 2002;288(12):1475-83.
Santacruz Escudero JM, Beltrán J, Palacios Á, Chimbí CM, Matallana D, Reyes P, et al. Neuropsychiatric symptoms as predictors of clinical course in neurodegeneration: A longitudinal study. Front Aging Neurosc. 2019 Jul 24;11.
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatr Clin Neurosci. 2000;12(2):233-9.
Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(7):685-95.
Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: Rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72(2):126-33.
Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJH, Pankratz VS, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study. Am J Psychiatry. 2014;171(5):572-81.
Kantarci K, Weigand SD, Przybelski SA, Preboske GM, Pankratz VS, Vemuri P, et al. MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology. 2013;81(2):126-33.
Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, et al. The Alzheimer's Disease Cooperative Study Prevention Instrument Project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014;4(3):509-16.
Khan TK. Clinical Diagnosis of Alzheimer's Disease. In: Biomarkers in Alzheimer's Disease. Academic Press; 2016. p. 27-48. Available from: https://www.sciencedirect.com/science/article/pii/B978012804832000002X
Masters MC, Morris JC, Roe CM. "Noncognitive" symptoms of early Alzheimer disease: A longitudinal analysis. Neurology. 2015;84(6):617-22.
Lee SAW, Sposato LA, Hachinski V, Cipriano LE. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2017;9(1):18.
Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of dementia in a psychiatric outpatient clinic. J Alzheimers Dis. 2019;70(2):503-11.
Botero-Rodríguez F, Córdoba Sastoque AM, Santacruz Escudero JM, Santamaría-García H. Neuropsychiatric symptoms in patients with neurocognitive disorder and their performance between mild and major stages. J Alzheimers Dis. 2022;85(4):1735-44.
Forlenza OV, Diniz BS, Stella F, Teixeira AL, Gattaz WF, Forlenza OV, et al. Mild cognitive impairment (part 1): clinical characteristics and predictors of dementia. Braz J Psychiatry. 2013;35(2):178-85.
Mallo SC, Ismail Z, Pereiro AX, Facal D, Lojo-Seoane C, Campos-Magdaleno M, et al. Assessing mild behavioral impairment with the mild behavioral impairment-checklist in people with mild cognitive impairment. J Alzheimers Dis. 2018;66(1):83-95.
Mallo SC, Ismail Z, Pereiro AX, Facal D, Lojo-Seoane C, Campos-Magdaleno M, et al. Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. Int Psychogeriatr. 2019;31(2):231-9.
Cui Y, Dai S, Miao Z, Zhong Y, Liu Y, Liu L, et al. Reliability and validity of the chinese version of the mild behavioral impairment checklist for screening for Alzheimer's disease. J Alzheimers Dis. 2019;70(3):747-56.
Mortby ME, Lyketsos CG, Geda YE, Ismail Z. Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. Int Psychogeriatr. 2018;16;30(2):167-9.
Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry. 2019;27(8):823-34.
Agüera-Ortiz LF, López-Álvarez J, del Nido-Varo L, Soria García-Rosel E, Pérez-Martínez DA, Ismail Z. Mild behavioural impairment as an antecedent of dementia: Presentation of the diagnostic criteria and the spanish version of the MBI-C scale for its evaluation. Rev Neurol. 2017;65(7):327-34.
Vik-Mo AO, Giil LM, Ballard C, Aarsland D. Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. Int J Geriatr Psychiatry. 2018;33(10):1361-9.
Yoon EJ, Ismail Z, Hanganu A, Kibreab M, Hammer T, Cheetham J, et al. Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease. Neurology. 2019;93(8):e766-77.
Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, et al. Mild behavioral impairment is associated with 3-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020;16(1):192-9.
Gill S, Mouches P, Hu S, Rajashekar D, MacMaster FP, Smith EE, et al. Using machine learning to predict dementia from neuropsychiatric symptom and neuroimaging data. J Alzheimer Dis. 2020;75(1):277-88.
Bermejo-Pareja F, del Ser T, Valentí M, de la Fuente M, Bartolome F, Carro E. Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions. Alzheimers Dement. 2020;16(8):1196-204.
Lee SAW, Sposato LA, Hachinski V, Cipriano LE. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2017;9(1):18.
World Health Organization. Towards a dementia plan: a WHO guide [Internet]. France; 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/272642/9789241514132-eng.pdf?sequence=1&isAllowed=y
Garcia-Cifuentes E, Botero-Rodríguez F, Ramirez Velandia F, Iragorri A, Marquez I, Gelvis-Ortiz G, et al. Muscular function as an alternative to identify cognitive impairment: A secondary analysis from SABE Colombia. Front Neurol. 2022;13:185.
Rosselli D, Hernández-Galvis J. The impact of aging on the Colombian health system. Salud Pública Méx. 2016;58(6):595-6. https://doi.org/10.21149/spm.v58i6.7880
Henríquez G, de Vries E. El efecto del envejecimiento para la carga de cáncer en Colombia: proyecciones para las primeras cinco localizaciones por departamento y sexo en Colombia, 2020 y 2050. Rev Colomb Cancerol. 2017;21(2):104-12.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.